MCMedicalCodingSoftware
HCPCSQ0000–Q9999

HCPCS QTemporary Codes

CMS's holding pen: drugs, supplies and services that need a code now and a permanent one later. Contrast agents and injectables dominate.

639 codes in the current CMS release, 584 of them still active.

55 terminated Q codes (no longer billable, kept for old claims)
  • Q0174Thiethylperazine maleate, 10 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
  • Q0220Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg
  • Q0221Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg
  • Q0222Injection, bebtelovimab, 175 mg
  • Q0239Injection, bamlanivimab-xxxx, 700 mg
  • Q0240Injection, casirivimab and imdevimab, 600 mg
  • Q0243Injection, casirivimab and imdevimab, 2400 mg
  • Q0244Injection, casirivimab and imdevimab, 1200 mg
  • Q0245Injection, bamlanivimab and etesevimab, 2100 mg
  • Q0247Injection, sotrovimab, 500 mg
  • Q0516Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 30-days
  • Q0517Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 60-days
  • Q0518Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 90-days
  • Q0519Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription injectable drug, per 30-days
  • Q0520Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription injectable drug, per 60-days
  • Q2017Injection, teniposide, 50 mg
  • Q2040Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion
  • Q4100Skin substitute, not otherwise specified
  • Q4106Dermagraft, per square centimeter
  • Q4119Matristem wound matrix, per square centimeter
  • Q4120Matristem burn matrix, per square centimeter
  • Q4129Unite biomatrix, per square centimeter
  • Q4131Epifix or epicord, per square centimeter
  • Q4172Puraply or puraply am, per square centimeter
  • Q4210Axolotl graft or axolotl dualgraft, per square centimeter
  • Q4228Bionextpatch, per square centimeter
  • Q4231Corplex p, per cc
  • Q4244Procenta, per 200 mg
  • Q4277Woundplus membrane or e-graft, per square centimeter
  • Q5102Injection, infliximab, biosimilar, 10 mg
  • Q5109Injection, infliximab-qbtx, biosimilar, (ixifi), 10 mg
  • Q5131Injection, adalimumab-aacf (idacio), biosimilar, 20 mg
  • Q5132Injection, adalimumab-afzb (abrilada), biosimilar, 10 mg
  • Q5139Injection, eculizumab-aeeb (bkemv), biosimilar, 10 mg
  • Q9969Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose
  • Q9970Injection, ferric carboxymaltose, 1mg
  • Q9972Injection, epoetin beta, 1 microgram, (for esrd on dialysis)
  • Q9973Injection, epoetin beta, 1 microgram, (non-esrd use)
  • Q9974Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg
  • Q9975Injection, factor viii fc fusion protein (recombinant), per iu
  • Q9976Injection, ferric pyrophosphate citrate solution, 0.1 mg of iron
  • Q9977Compounded drug, not otherwise classified
  • Q9978Netupitant 300 mg and palonosetron 0.5 mg
  • Q9979Injection, alemtuzumab, 1 mg
  • Q9980Hyaluronan or derivative, genvisc 850, for intra-articular injection, 1 mg
  • Q9981Rolapitant, oral, 1 mg
  • Q9984Levonorgestrel-releasing intrauterine contraceptive system (kyleena), 19.5 mg
  • Q9985Injection, hydroxyprogesterone caproate, not otherwise specified, 10 mg
  • Q9986Injection, hydroxyprogesterone caproate, (makena), 10 mg
  • Q9987Pathogen(s) test for platelets
  • Q9988Platelets, pheresis, pathogen-reduced, each unit
  • Q9989Ustekinumab, for intravenous injection, 1 mg
  • Q9993Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg
  • Q9994In-line cartridge containing digestive enzyme(s) for enteral feeding, each
  • Q9995Injection, emicizumab-kxwh, 0.5 mg
HCPCS Level II2026Q3-Jul· effective July 1, 2026